The effects of edema on urethral dose following palladium-103 prostate brachytherapy

Medical Dosimetry

Volumn 27, Issue 3, 2002, Pages 221-225

  Gejerman, Glen ^a   Mullokandov, Eduard ^a   Saini, A J ^a   Lanteri, Vincent ^a   Scheuch, John ^a   Vitenson, Jack ^a   Rosen, Jay ^a   Garden, Richard ^a   Sawczuk, Ihor ^a  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Postimplant dosimetry; Prostate brachytherapy; Urethral dose

Indexed keywords

PALLADIUM 103;

ARTICLE; BALLOON CATHETER; BEAM THERAPY; BRACHYTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSIMETRY; EDEMA; HUMAN; MALE; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIATION DOSE; RADIATION SICKNESS; REGRESSION ANALYSIS; URETHRA; UROGRAPHY;

BRACHYTHERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; EDEMA; HUMANS; MALE; PALLADIUM; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOTHERAPY DOSAGE; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; URETHRA; URETHRAL DISEASES;

EID: 0036430275     PISSN: 09583947     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-3947(02)00143-7     Document Type: Article

References (24)

1. Catalona W.J., Smith D.S., Ratliff T.L., et al. Detection of organ confined prostate cancer is increased through prostate specific antigen based screening. JAMA. 49:1993;33.
2. Ragde H., Abdel-Aziz A.E., Snow P.B., et al. Ten year disease free survival after transperineal sonography guided Iodine-125 brachytherapy with or without 45-Gray external beam irradiation in the treatment of patients with clinically localized low to high Gleason grade prostate carcinoma. Cancer. 83:1998;989-1001.
3. Blasko J.C., Grimm P.D., Sylvester J.E., et al. Palladium-103 brachytherapy for prostate carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 46:2000;839-850.
4. Dattoli M., Wallner K., Sorace R., et al. Palladium-103 brachytherapy and external beam irradiation for clinically localized high risk prostatic carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 35:1996;875-879.
5. Critz F.A., Williams H., Levinson K.A., et al. Simultaneous irradiation for prostate cancer Intermediate results with modern techniques. Urology. 164:2000;738-743.
6. Kleinberg L., Wallner K., Roy J., et al. Treatment related symptoms during the first year following transperineal I-125 prostate implantation. Int. J. Radiat. Oncol. Biol. Phys. 28:1994;985-990.
7. Nag S., Scaperoth D.D., Badalament R., et al. Transperineal palladium-103 prostate brachytherapy Analysis of morbidity and seed migration. Urology. 45:1995;87-92.
8. Gelblum D.Y., Potters L., Ashley R., et al. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int. J. Radiat. Oncol. Biol. Phys. 45:1999;59-67.
9. Wallner K., Roy J., Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate implantation. Int. J. Radiat. Oncol. Biol. Phys. 32:1995;465-471.
10. Desai J., Stock R.G., Stone N.N. Acute urinary morbidity following I-125 interstitial implant of the prostate gland. Radiat. Oncol. Invest. 6:1998;135-141.
11. Nath R., Anderson L.L., Luxton G., et al. Dosimetry of interstitial brachytherapy sources Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med. Phys. 22:1995;209-234.
12. Narayana V., Roberson P.L., Pu A.T., et al. Impact of differences in ultrasound and computed tomography volumes on treatment planning of permanent prostate implants. Int. J. Radiat. Oncol. Biol. Phys. 37:1997;1181-1185.
13. Prestidge B.R., Bice W.S., Kiefer E.J., et al. Timing of computed tomography-based postimplant assessment following permanent transperineal prostate brachytherapy. Int. J. Radiat. Biol. Phys. 40:1998;1111-1115.
14. Yue N., Dicker A.P., Corn B.W., et al. A dynamic model for the estimation of optimum timing of computed tomography scan for dose evaluation of I-125 or Pd-103 seed implant of prostate. Int. J. Radiat. Oncol. Biol. Phys. 43:1999;447-454.
15. Waterman F.M., Dicker A.P. Determination of the urethral dose in prostate brachytherapy when the urethra cannot be visualized in the postimplant CT scan. Med. Phys. 27:2000;448-451.
16. Merrick G.S., Butler W.M., Lief J.H., et al. Temporal resolution of urinary morbidity following prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 47:2000;121-128.
17. Butler W.M., Merrick G.S., Dorsey A.T., et al. Comparison of dose length, area, and volume histograms as quantifiers of urethral dose in prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 48:2000;1575-1582.
18. Cox J.D., Stetz J., Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int. J. Radiat. Oncol. Biol. Phys. 31:1995;1341-1346.
19. Waterman M.F., Yue N., Corn B.W., et al. Edema associated with I125 or Pd103 prostate brachytherapy and its impact on post implant dosimetry An analysis based on serial CT acquisition. Int. J. Radiat. Oncol. Biol. Phys. 41:1998;1069-1077.
20. Waterman M.F., Yue N., Reisinger S., et al. Effect of edema on the post-implant dosimetry of an I125 prostate implant A case study. Int. J. Radiat. Oncol. Biol. Phys. 38:1997;335-339.
21. Moerland M.A., Wijderman H.K., Beersma R., et al. Evaluation of permanent I125 implants using radiography and magnetic resonance imaging. Int. J. Radiat. Oncol. Biol. Phys. 37:1997;927-933.
22. Butler W.M., Merrick G.S., Dorsey A.T., et al. Isotope choice and the effect of edema on prostate brachytherapy dosimetry. Med. Phys. 27:2000;1067-1075.
23. Waterman F.M., Dicker A.P. The impact of post implant edema on the urethral dose in prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 47:2000;661-664.
24. Nag S., Bice W., DeWyngaert K., et al. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int. J. Radiat. Oncol. Biol. Phys. 46:2000;221-230.